Kirby McInerney LLP | Financial Litigation Law Firm | <b ><span >Sio Gene Therapies, Inc. </span ></b >Investigation
This links to the home page

Sio Gene Therapies, Inc. Investigation

The law firm of Kirby McInerney LLP is investigating potential claims against Sio Gene Therapies, Inc. f/k/a Axovant Gene Therapies Ltd. (“Sio” or the “Company”) (NASDAQ: SIOX f/k/a AXGT). The investigation focuses on whether the Company and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On October 29, 2020, Sio disclosed that manufacturing delays would potentially postpone the start of enrollment in the Company’s planned randomized, sham-controlled trial of AXO-Lenti-PD gene therapy for Parkinson’s disease, and that the trial seemed unlikely to enroll patients by the end of the calendar year 2021.

On this news, Sio’s stock price fell $1.52 per share, or 41.64%, to close at $2.13 per share on October 30, 2020.

If you purchased or otherwise acquired Sio securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Sio Gene Therapies, Inc. Investor Contact Form